Converted Users Sample Clauses
Converted Users
Authorized Users Authorized Users" are:
Authorized User You may request us to issue a Card to an individual who has no financial responsibility under this Agreement. An Authorized User has the same access to your Account as you do, subject to any limitations we may impose. An Authorized User has no authority to add or delete Cardholders, request a replacement Card or terminate or modify this Agreement. You may terminate an Authorized User’s authority to access your Account at any time. To do this, you must return the Card to PenFed. You agree that you are responsible for all charges and cash advances made by an Authorized User, including charges made before the Card is returned, recurring charges, or charges made without the use of the Card initiated by the Authorized User after termination of the Authorized User’s access.
Restricted Use Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adalimumab (Humira® / Biosimilar) NHSE Children with Severe Refractory Uveitis with onset in childhood (age 2 or more up to 18 or less) - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adalimumab (biosimilar) (Imraldi® / Amjevita®) ICB Peripheral spondyloarthritis - following use of 3 DMARDs, as per local pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adalimumab (biosimilar) various ICB weekly use for dose escalations in NICE-approved rheumatology indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adefovir Hepsera ® NHSE Hepatitis B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG165 - Oct 17 Double Red ADHD drugs - various (Various) ICB First-line use in children and adolescents with ADHD - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 Double Red ADHD drugs - various (Various) ICB Use in pre-school children - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 BLACK Afamelanotide Scenesse® NHSE erythropoietic protoporphyria Not commissioned. No NHS prescribing in primary or secondary care HST27 – July 2023 Hospital Afatinib ▼ (Giotrif® ▼) NHSE Treatment of epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer - as per NICE TA 310 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA310 - April 2014 BLACK Afatinib ▼ (Giotrif® ▼) NHSE Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy - as per NICE TA 444 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA444 - May 17 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Aflibercept (Eylea®) ICB Treatment of Wet Age-related Macular Degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 Hospital Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 Hospital Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) in new patients Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 Hospital Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema secondary to central retinal vein occlusion (CRVO) - as per NICE TA 305 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA305 - Feb 14 BLACK Aflibercept (Zaltrap®) NHSE Treatment of metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (along with irinotecan and fluorouracil- based therapy) - as per NICE TA 307 - NICE Do Not Do Not commissioned. No NHS prescribing in primary or secondary care TA307 - Mar 14 Hospital Aflibercept (Eylea®) ICB Treatment of visual impairment caused by diabetic macular oedema (DMO) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA346 - Jul 15 Hospital Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema after branch retinal vein occlusion - as per NICE TA 409 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA409 - Sep 16 Hospital Aflibercept (Eylea®) ICB Treatment of visual impairment due to myopic choroidal neovascularisation in adults - as per NICE TA 486 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA486 - Nov 17 Hospital Aflibercept (Eylea®) ICB Treatment of Diabetic Macular Oedema (DMO) as part of a treat and extend regimen in line with the locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Aflibercept (Eylea®) ICB Treatment of Wet Age-related Macular Degeneration (AMD) as part of a treat and extend regimen in line with the locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Aflibercept (switched to Ranibizumab (Lucentis®) (Eylea®) ICB Switching between products in the treatment of Wet Age-related Macular Degeneration (AMD) in previously treated patients who have not responded adequately to, or who have intolerance to aflibercept (Eylea®) - as per locally commissioned pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NG82 - Jan 18 Hospital Agalsidase alfa and beta (Replagal® (alpha) / Fabrazyme® (beta)) NHSE Fabry disease (α-galactosidase A deficiency) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Agomelatine (Valdoxan®) ICB 4th line use in depression where other treatments have failed or not been tolerated (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA231 - Sep 11 Hospital Albumin bound paclitaxel Abraxane ® NHSE with gemcitabine for untreated metastatic pancreatic cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA476 - Sep 17 Hospital Albutrenpenonacog alfa (Idelvion) NHSE Haemophilia B - as per NHS England policy SSC1652 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. DM Albutropin NHSE Adult onset growth hormone deficiency . Discontinued Medicines NICE has not issued any guidance. Hospital Aldesleukin (Proleukin) NHSE Cancer - metastatic renal cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alectinib (Alecensa®) NHSE Untreated ALK-positive advanced non- small-cell lung cancer - as per NICE TA 536 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA536 - Aug 18 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Alectinib ▼ (Alecensa® ▼) NHSE Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - as per NICE TA 438 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA438 - Mar 17 Hospital Alemtuzumab (Lemtrada®) NHSE Chronic lymphocytic leukaemia (CLL) as per NHS England policy 2013 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alemtuzumab (Lemtrada®) NHSE Pre-transplant immunosuppression Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alemtuzumab (MabCampath®) NHSE Behcet's syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alemtuzumab ▼ (Lemtrada® ▼) NHSE Treatment of adults with relapsing- remitting multiple sclerosis (RRMS) - as per NICE TA 312 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA312 - May 14 Double Red Alendronate / Vitamin D3 combination (Fosavance®) ICB Treatment of post menopausal osteoporosis in women at risk of vitamin D deficiency Not recommended for routine use NICE has not issued any guidance. GREEN Alendronic acid (sodium alendronate) (Generics available) ICB Secondary prevention of osteoporotic fragility fractures in postmenopausal women - as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA161 - Oct 08 GREEN Alendronic acid (sodium alendronate) (Generic available) ICB Primary prevention of osteoporotic fragility fractures in postmenopausal women as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA464 - Aug 17 ADVICE Alfacalcidol (AlfaD®, One- Alpha®) ICB Preparation for hyperparathyroidectomy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Alglucosidase alfa (Myozyme®) NHSE Pompe disease (a lysosomal storage disorder caused by deficiency of acid alpha-glucosidase) - as per NHS England Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Alimemazine (Trimeprazine) (Generics) ICB Sedative in children / general antihistamine Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Alipogene tiparvovec (Glybera®) NHSE (Gene therapy treatment for ) Lipoprotein lipase deficiency - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alirocumab ▼ (Praluent® ▼) ICB Treating primary hypercholesterolaemia and mixed dyslipidaemia - as per NICE TA 393 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA393 - Jun 16 BLACK Aliskiren ▼ (Rasilez® ▼) ICB Treatment of essential hypertension - as per NICE CG 127 Not commissioned. No NHS prescribing in primary or secondary care CG127 - Sep 11 Double Red Alisporivir ((aka Debio 025 / DEB025 / UNIL- 025)) NHSE Viral Hepatitis C - as per NHSE policy Not recommended for routine use NICE has not issued any guidance. Hospital Alitretinoin (Toctino®) ICB Treatment of severe chronic hand eczema - as per NICE TA 177 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA177 - Aug 09 BLACK Alpelisib Piqray® NHSE with fulvestrant for treating hormone- receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA652 – October 2020 Hospital Alpelisib Piqray® NHSE with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA816 – August 2022 Double Red Alpha blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 . Not recommended for routine use CG101 - Jul 10 Hospital Alpha-mannosidase - recombinant human (Lamazym®) NHSE Alpha Mannosidase deficiency - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Alprostadil cream (Vitaros®) ICB Erectile dysfunction (as per SLS conditions only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Alteplase (Actilyse®) ICB Treatment of acute ischaemic stroke - as per NICE TA 264 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA264 - Sep 12 Double Red Amantadine Hydrochloride (Lysovir®) ICB Treatment and prophylaxis of influenza Not recommended for routine use TA168 - Feb 09 Hospital Ambrisentan (Volibris® ▼) NHSE Pulmonary Arterial Hypertension - specialist centre only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Amifampridine (phosphate) ▼ (Firdapse® ▼) NHSE Treatment of myasthenias - ▇▇▇▇▇▇▇- ▇▇▇▇▇ syndrome - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Amikacin - liposomal for inhalation (Arikace®) NHSE Gram-negative bacterial infection in Cystic Fibrosis . Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Amikacin (for inhalation) (Amikin®) NHSE Gram-negative bacterial infection in Cystic Fibrosis Not recommended for routine use NICE has not issued any guidance. BLACK Aminobenzoic acid (capsules and powder) (Potaba®) ICB Peyronie's disease, Scleroderma Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. AMB 2 Amiodarone (Cordarone X®) ICB Supraventricular and ventricular arrhythmias Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly CG180 - Jun 14 BLACK Amivantamab n/a NHSE EGFR exon 20 insertion mutation- positive advanced non-small-cell lung cancer after platinum-based chemotherapy Not commissioned. No NHS prescribing in primary or secondary care TA850 – December 2022 BLACK Amorolfine (Loceryl and other equivalent preparations) ICB Fungal nail infections Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Amphotericin B, itraconazole & voriconazole (Various) NHSE Chronic Pulmonary Aspergillosis (CPA) - specialist centre only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Anabasum NHSE Scleroderma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB Anagrelide ▼ (Xagrid® ▼ / Agrelin® / Agrylin®) ICB Thrombocythaemia Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. Hospital Anakinra Kineret® NHSE Still’s disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA685 – March 2021 Hospital Anakinra (Kineret®) NHSE Cryopyrin-associated periodic syndrome (CAPS) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Anakinra (Kineret®) NHSE Adult onset Still's disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Anakinra (Kineret®) NHSE Rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NG100 - Oct 2020 Hospital Anakinra (Kineret®) NHSE Juvenile Idiopathic Arthritis (JIA) Res
Users There is no limit to the number of users who can access the Software. You can invite any person You wish to access the Software.
Restricted Use of Confidential Information (a) Each Receiving Party acknowledges the confidential and proprietary nature of the Confidential Information of the Disclosing Party and agrees that such Confidential Information (i) shall be kept confidential by the Receiving Party; (ii) shall not be used for any reason or purpose other than to evaluate and consummate the Contemplated Transactions; and (iii) without limiting the foregoing, shall not be disclosed by the Receiving Party to any Person, except in each case as otherwise expressly permitted by the terms of this Agreement or with the prior written consent of an authorized representative of Seller with respect to Confidential Information of Seller(each, a "Seller Contact") or an authorized representative of Buyer with respect to Confidential Information of Buyer (each, a "Buyer Contact"). Each of Buyer and Seller shall disclose the Confidential Information of the other party only to its Representatives who require such material for the purpose of evaluating the transactions contemplated herein and are informed by Buyer or Seller, as the case may be, of the obligations of this Article 12 with respect to such information. Each of Buyer and Seller shall (iv) enforce the terms of this Article 12 as to its respective representatives; (v) take such action to the extent necessary to cause its representatives to comply with the terms and conditions of this Article 12; and (vi) be responsible and liable for any breach of the provisions of this Article 12 by it or its representatives. (b) Unless and until this Agreement is terminated, Seller shall maintain as confidential any Confidential Information (including for this purpose any information of Seller of the type referred to in Sections 12.l(a)(i), (ii) and (iii), whether or not disclosed to Buyer) of the Seller or Shareholders relating to any of the Assets or the Assumed Liabilities. (c) From and after the Closing, the provisions of Section 12.2(a) above shall not apply to or restrict in any manner Buyer's use of any Confidential Information of the Seller relating to any of the Assets or the Assumed Liabilities.